
The objective was to develop and validate a risk score for subclinical RA-ILD patients. The discovery population included 163 patients with RA, and the replication population included 89 patients with RA. The study developed and validated a risk score that could help identify patients at high risk of subclinical RA‐ILD. Our findings support a significant contribution of MUC5B rs35705950 to subclinical RA‐ILD risk.
Like
Save
Share